Erratum : VINCENT HAUFROID and PHILIPPE HANTSON. (2015) CYP2D6 genetic polymorphisms and their relevance for poisoning due to amphetamines, opioid analgesics and antidepressants.(Clinical Toxicology (2015) (1-10) DOI:/10.3109/15563650.2015.1049355);CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants

Clinical Toxicology

Volumn 53, Issue 6, 2015, Pages 501-510

  Haufroid, Vincent ^a,b   Hantson, Philippe ^a,b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Antidepressants; CYP2D6; Designer drugs; Opioid analgesics; Poisoning; Toxicogenetics

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; AMITRIPTYLINE; AMPHETAMINE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; CODEINE; CYTOCHROME P450 2D6; FLUOXETINE; HYDROMORPHONE; MORPHINE; NALOXONE; NORTRIPTYLINE; OPIATE; PARACETAMOL; TRAMADOL; VENLAFAXINE; AMPHETAMINE DERIVATIVE; NARCOTIC ANALGESIC AGENT;

ALLELE; BIOTRANSFORMATION; CASE CONTROL STUDY; CENTRAL NERVOUS SYSTEM; GENETIC POLYMORPHISM; HUMAN; IN VITRO STUDY; INTOXICATION; MEDLINE; NEUROLOGIC DISEASE; NEUROTOXICITY; REVIEW; TOXICOGENETICS; TOXICOLOGICAL PARAMETERS; DRUG OVERDOSE; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PHENOTYPE; RISK ASSESSMENT; RISK FACTOR;

AMPHETAMINES; ANALGESICS, OPIOID; ANTIDEPRESSIVE AGENTS; BIOTRANSFORMATION; CYTOCHROME P-450 CYP2D6; DRUG OVERDOSE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PHENOTYPE; POISONING; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS; TOXICOGENETICS;

EID: 84931319712     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2015.1059025     Document Type: Erratum

References (64)

1. Daly AK. Molecular basis of polymorphic drug metabolism. JMol Med 1995; 73: 539-553.
2. Wilkinson GR. Drug metabolism and variability among patients in drug response. New Engl JMed 2005; 352: 2211-2221.
3. CYP2D6 allele nomenclature. http://www.cypalleles.ki.se/cyp2d6. htm. (Last accessed on August 2014 ).
4. Frank D, Jaehde U, Fuhr U. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur JClin Pharmacol 2007; 63: 321-333.
5. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008; 83: 234-242.
6. Clinical Pharmacogenetics Implementation Consortium (CPIC) for codeine, http://www.pharmgkb.org/guideline/PA166104996. (Last accessed on September 2014 ).
7. Luminex 2D6v3 FDA approved kit, Http://www.luminexcorp.com/ Products/Assays/ClinicalDiagnostics/xTAGCYP2D6/. (Last accessed on September 2014 ).
8. Dutch Pharmacogenetics Working Group Guidelines (DPWG) for codeine, http://www.pharmgkb.org/guideline/PA166104970. (Last accessed on September 2014 ).
9. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002; 3: 229-243.
10. Ingelman-Sundberg M. Pharmacogenetics of cytochrome p450 and its applications in drug therapy: The past, present and future. Trends Pharmacol Sci 2004; 25: 193-200.
11. http://medicine.iupui.edu/clinpharm/ddis/main-table/. (Last accessed on August 2014 ).
12. Law MY, Moody DE. Urinary excretion of amfetamine and 4 '-hydroxyamphetamine by sprague dawley and dark agouti rats. Life Sci 1994; 54: 1073-1079.
13. Maurer HH, Kraemer T, Springer D, Staack RF. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amfetamine (ecstasy), piperazine, and pyrrolidinophenone types: A synopsis. Ther Drug Monit 2004; 26: 127-131.
14. Schwab M, Seyringer E, Brauer RB, Hellinger A, Griese EU. Fatal MDMA intoxication. Lancet 1999; 353: 593-594.
15. Jamei M, Heydari A, Yeo KR, de la Torre R, Farre M, et al. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. JPsychopharmacol 2006; 20: 842-849.
16. Carmo H, Brulport M, Hermes M, Oesch F, Silva R, Ferreira LM, et al. Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine ('Ecstasy ' ) cytotoxicity. Pharmacogenet Genomics 2006; 16: 789-799.
17. Cherner M, Bousman C, Everall I, Barron D, Letendre S, Vaida F, et al. Cytochrome P450-2D6 extensive metabolizers are more vulnerable to methamfetamine-associated neurocognitive impairment: Preliminary fi ndings. JInt Neuropsychol Soc 2010; 16: 890-901.
18. Sutter ME, Gaedigk A, Albertson TE, Southard J, Owen KP, Mills LD, Diercks DB. Polymorphisms in CYP2D6 may predict methamfetamine related heart failure. Clin Toxicol 2013; 51: 540-544.
19. Volpe DA, McMahon Tobin GA, Mellon RD, Katki AG, Parker RJ, Colatsky T, et al. Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol 2011; 59: 385-390.
20. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. New Engl JMed 2004; 351: 2827-2831.
21. Voronov P, Przybylo HJ, Jagannathan N. A pnea in a child after oral codeine: A genetic variant-an ultra-rapid metabolizer. Paediatr Anaesth 2007; 17: 684-687.
22. Friedrichsdorf SJ, Nugent AP, Strobl AQ. Codeine-associated pediatric deaths despite using recommended dosing guidelines: three case reports. JOpioid Manag 2013; 9: 151-155.
23. Frost J, Helland A, Nordrum IS, Slordal L. Investigation of morphine and morphine glucuronide levels and cytochrome P450 isoenzyme 2D6 genotype in codeine-related deaths. Forensic Sci Int 2012; 220: 6-11.
24. Ferreiros N, Dresen S, Hermanns-Clausen M, Auwaerter V, Thierauf A, Muller C, et al. Fatal and severe codeine intoxication in 3-year-old twins-interpretation of drug and metabolite concentrations. Int JLegal Med 2009; 123: 387-394.
25. Shaw KD, Amstutz U, Jimenez-Mendez R, Ross CJ, Carleton BC. Suspected opioid overdose case resolved by CYP2D6 genotyping. Ther Drug Monit 2012; 34: 121-123.
26. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006; 368: 704.
27. Madadi P, Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder JS, et al. Safety of codeine during breastfeeding: Fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can Fam Physician 2007; 53: 33-35.
28. Madadi P, Ross CJ, Hayden MR, Carleton BC, Gaedigk A, Leeder JS, Koren G. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: A case-control study. Clin Pharmacol Ther 2009; 85: 31-35.
29. Willmann S, Edginton AN, Coboeken K, Ahr G, Lippert J. Risk to the breast-fed neonate from codeine treatment to the mother: A quantitative mechanistic modeling study. Clin Pharmacol Ther 2009; 86: 634-643.
30. Juurlink DN, Gomes T, Guttmann A, Hellings C, Sivilotti ML, Harvey MA, Mamdani MM. Postpartum maternal codeine therapy and the risk of adverse neonatal outcomes: A retrospective cohort study. Clin Toxicol 2012; 50: 390-395.
31. Madadi P, Moretti M, Djokanovic N, Bozzo P, Nulman I, Ito S, Koren G. Guidelines for maternal codeine use during breastfeeding. Can Fam Physician 2009; 55: 1077-1078.
32. Kirchheiner J, Keulen JT, Bauer S, Roots I, Brockmoller J. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. JClin Psychopharmacol 2008; 28: 78-83.
33. Levo A, Koski A, Ojanpera I, Vuori E, Sajantila A. Post-mortem snp analysis of CYP2D6 gene revealScorrelation between genotype and opioid drug (tramadol) metabolite ratios in blood. Forensic Sci Int 2003; 135: 9-15.
34. Gleason PP, Frye RF, O'Toole T. Debilitating reaction following the initial dose of tramadol. Ann Pharmacother 1997; 31: 1150-1152.
35. Stamer UM, Stuber F, Muders T, Musshoff F. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth Analg 2008; 107: 926-929.
36. Elkalioubie A, Allorge D, Robriquet L, Wiart JF, Garat A, Broly F, Fourrier F. Near-fatal tramadol cardiotoxicity in a CYP2D6 ultrarapid metabolizer. Eur JClin Pharmacol 2011; 67: 855-858.
37. Jannetto PJ, Wong SH, Gock SB, Laleli-Sahin E, Schur BC, Jentzen JM. Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: genotyping cytochrome P450 2D6 for oxycodone cases. JAnal Toxicol 2002; 26: 438-447.
38. Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, et al. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic effi cacy and safety. Br JPharmacol 2010; 160: 919-930.
39. Andreassen TN, Eftedal I, Klepstad P, Davies A, Bjordal K, Lundstrom S, et al. Do CYP2D6 genotypes refl ect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study. Eur JClin Pharmacol 2012; 68: 55-64.
40. Madadi P, Hildebrandt D, Gong IY, Schwarz UI, Ciszkowski C, Ross CJ, et al. Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions. Pediatrics 2010; 126: e986-989.
41. Xu BQ, Aasmundstad TA, Christophersen AS, Morland J, Bjorneboe A. Evidence for CYP2D1-mediated primary and secondary o-dealkylation of ethylmorphine and codeine in rat liver microsomes. Biochem Pharmacol 1997; 53: 603-609.
42. Aasmundstad TA, Xu BQ, Johansson I, Ripel A, Bjorneboe A, Christophersen AS, et al. Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose. Br JClin Pharmacol 1995; 39: 611-620.
43. Xu BQ, Aasmundstad TA, Bjorneboe A, Christophersen AS, Morland J. Ethylmorphine o-deethylation in isolated rat hepatocytes. Involvement of codeine o-demethylation enzyme systems. Biochem Pharmacol 1995; 49: 453-460.
44. Helland A, Isaksen CV, Slordal L. Death of a 10-month-old boy after exposure to ethylmorphine. JForensic Sci 2010; 55: 551-553.
45. Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for codeine therapy in the context of cytochrome p450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 2012; 91: 321-326.
46. Koski A, Sistonen J, Ojanpera I, Gergov M, Vuori E, Sajantila A. CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies. Forensic Sci Int 2006; 158: 177-183.
47. Smith JC, Curry SC. Prolonged toxicity after amitriptyline overdose in a patient defi cient in CYP2D6 activity. JMed Toxicol 2011; 7: 220-223.
48. Jornil J, Jensen KG, Larsen F, Linnet K. Risk assessment of accidental nortriptyline poisoning: The importance of cytochrome P450 for nortriptyline elimination investigated using a population-based pharmacokinetic simulator. Eur JPharm Sci 2011; 44: 265-272.
49. Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 2013; 93: 402-408.
50. Koski A, Ojanpera I, Sistonen J, Vuori E, Sajantila A. A fatal doxepin poisoning associated with a defective CYP2D6 genotype. Am JForensic Med Pathol 2007; 28: 259-261.
51. Gex-Fabry M, Balant-Gorgia AE, Balant LP, Rudaz S, Veuthey JL, Bertschy G. Time course of clinical response to venlafaxine: relevance of plasma level and chirality. Eur JClin Pharmacol 2004; 59: 883-891.
52. McAlpine DE, Biernacka JM, Mrazek DA, O'K ane DJ, Stevens SR, Langman LJ, et al. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. Ther Drug Monit 2011; 33: 14-20.
53. Lessard E, Yessine MA, Hamelin BA, O'Hara G, LeBlanc J, Turgeon J. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 1999; 9: 435-443.
54. Langford NJ, Martin U, Ruprah M, Ferner RE. Alternative venlafaxine kinetics in overdose. JClin Pharm Ther 2002; 27: 465-467.
55. Vinetti M, Haufroid V, Capron A, Classen JF, Marchandise S, Hantson P. Severe acute cardiomyopathy associated with venlafaxine overdose and possible role of CYP2D6 and CYP2C19 polymorphisms. Clin Toxicol 2011; 49: 865-869.
56. Shams ME, Arneth B, Hiemke C, Dragicevic A, Muller MJ, Kaiser R, et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. JClin Pharm Ther 2006; 31: 493-502.
57. Launiainen T, Rasanen I, Vuori E, Ojanpera I. Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions. Int JLegal Med 2011; 125: 349-358.
58. Kingback M, Karlsson L, Zackrisson AL, Carlsson B, Josefsson M, Bengtsson F, et al. Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood. Forensic Sci Int 2012; 214: 124-134.
59. Jornil J, Nielsen TS, Rosendal I, Ahlner J, Zackrisson AL, Boel LW, Brock B. A poor metabolizer of both CYP2C19 and CYP2D6 identifi ed by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine. Forensic Sci Int 2013; 226: e26-31.
60. Sallee FR, DeVane CL, Ferrell RE. Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic defi ciency. JChild Adolesc Psychopharmacol 2000; 10: 27-34.
61. Sato A, Okura Y, Minagawa S, Ohno Y, Fujita S, K ondo D, et a l. L ifethreatening serotonin syndrome in a patient with chronic heart failure and CYP2D6 ∗ 1/ ∗ 5. Mayo Clin Proc 2004; 79: 1444-1448.
62. Hyttel J, Bogeso K P, Perregaard J, Sanchez C. The pharmacological effect of citalopram residues in the (s)-(-)-enantiomer. JNeural Transm Gen Sect 1992; 88: 157-160.
63. Carlsson B, Holmgren A, Ahlner J, Bengtsson F. Enantioselective analysis of citalopram and escitalopram in postmortem blood together with genotyping for CYP2D6 and CYP2C19. JAnal Toxicol 2009; 33: 65-76.
64. Holmgren P, Carlsson B, Zackrisson AL, Lindblom B, Dahl ML, Scordo MG, et al. Enantioselective analysis of citalopram and its metabolites in postmortem blood and genotyping for CYP2D6 and CYP2C19. JAnal Toxicol 2004; 28: 94-104.